Figure 5From: Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain Cost-effectiveness acceptability curves: Azacitidine vs. BSC and Azacitidine vs. LDC. AZA = azacitidine; BSC = best supportive care; LDC = low dose chemotherapy; CCR = conventional care regimen.Back to article page